The approved product has an estimated market size of US$ 44.5 million for the twelve months ending January 2024
To accelerate the development of next-generation radioconjugates to treat cancer
Winlevi is indicated for the topical treatment of acne vulgaris in patients 12 years of age and older
Acquisition to further expand the Alexion, AstraZeneca Rare Disease pipeline beyond complement inhibition
The first and only oral androgen deprivation therapy treatment for men with advanced prostate cancer
India is contributing 13% to the global asthma burden and a disproportionate 43% of the global asthma deaths.
Arun is currently working as Vice President (Strategy) in Solara leading Business finance & Strategy function
The product combines proven efficacy of Doxylamine succinate 20 mg and Pyridoxine hydrochloride 20 mg in an Extended Release formulation
The company will provide comprehensive response to USFDA for the observations
Subscribe To Our Newsletter & Stay Updated
